Rankings
▼
Calendar
EYPT (EyePoint Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena
EYPT
EyePoint Pharmaceuticals, Inc.
Mkt Cap
$1B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$31M
Net Income (TTM)
-$232M
EPS (TTM)
-$3.16
Free Cash Flow (TTM)
-$243M
Gross Margin
93.4%
Op. Margin
-776.0%
Net Margin
-739.4%
FCF Margin
-775.8%
P/S Ratio (TTM)
42.5x
P/E Ratio (TTM)
—
YoY Rev Growth
-27.5%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$8M
$7M
-$22M
Q2 23
$9M
$7M
-$23M
Q3 23
$15M
$14M
-$14M
Q4 23
$14M
$13M
-$16M
Q1 24
$12M
$11M
-$33M
Q2 24
$9M
$8M
-$35M
Q3 24
$11M
$10M
-$33M
Q4 24
$12M
$11M
-$45M
Q1 25
$24M
$24M
-$49M
Q2 25
$5M
$5M
-$62M
Q3 25
$966K
$245K
-$62M
Q4 25
$620K
$245K
-$70M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
33.5x
—
Q2 23
35.7x
—
Q3 23
31.4x
—
Q4 23
29.0x
—
Q1 24
26.7x
—
Q2 24
26.5x
—
Q3 24
29.2x
—
Q4 24
30.8x
—
Q1 25
23.8x
—
Q2 25
25.7x
—
Q3 25
31.5x
—
Q4 25
42.5x
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$17M
-$17M
Q2 23
$57M
$57M
Q3 23
-$15M
-$17M
Q4 23
-$23M
-$24M
Q1 24
-$31M
-$32M
Q2 24
-$20M
-$21M
Q3 24
-$39M
-$41M
Q4 24
-$36M
-$36M
Q1 25
-$53M
-$53M
Q2 25
-$63M
-$64M
Q3 25
-$59M
-$60M
Q4 25
-$65M
-$66M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$484K
Q2 23
$396K
Q3 23
$2M
Q4 23
$883K
Q1 24
$1M
Q2 24
$900K
Q3 24
$2M
Q4 24
$384K
Q1 25
$276K
Q2 25
$1M
Q3 25
$798K
Q4 25
$986K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
-17.3%
+6.0%
Q2 23
-21.3%
+3.5%
Q3 23
+51.8%
+4.2%
Q4 23
+33.2%
-44.0%
Q1 24
+52.1%
+53.9%
Q2 24
+4.1%
+38.2%
Q3 24
-30.8%
+46.2%
Q4 24
-17.4%
+87.0%
Q1 25
+109.3%
+62.8%
Q2 25
-43.7%
+53.5%
Q3 25
-90.8%
+45.6%
Q4 25
-94.6%
+24.9%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$3M
39.7%
Q2 23
$2M
19.6%
Q3 23
$4M
23.9%
Q4 23
$4M
25.6%
Q1 24
$13M
108.7%
Q2 24
$9M
91.7%
Q3 24
$7M
70.8%
Q4 24
$8M
68.2%
Q1 25
$8M
32.0%
Q2 25
$7M
128.9%
Q3 25
$6M
665.4%
Q4 25
$7M
1088.5%
marketcaparena.com
OpEx Breakdown
R&D
G&A
S&M
Quarter
R&D
G&A
S&M
Q1 23
$14M
$9M
$6M
Q2 23
$16M
$9M
$5M
Q3 23
$17M
$11M
$479K
Q4 23
$18M
$11M
$185K
Q1 24
$30M
$14M
$6K
Q2 24
$30M
$13M
$50K
Q3 24
$30M
$13M
$24K
Q4 24
$43M
$13M
$51K
Q1 25
$59M
$14M
$35K
Q2 25
$55M
$12M
$35K
Q3 25
$48M
$14M
$26K
Q4 25
$59M
$11M
—
marketcaparena.com
Revenue Segments
License And Collaboration Agreement
Product
Royalty
Y U T I Q Product
Quarter
License And Collaboration Agreement
Product
Royalty
Y U T I Q Product
Q1 23
$34K
$7M
$255K
—
Q2 23
$4M
$5M
$235K
—
Q3 23
$14M
$816K
$249K
—
Q1 25
$11M
$715K
$13M
$600K
Q2 25
$5M
—
—
—
Q3 25
$150K
$582K
$234K
—
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$106M
$17M
$122M
Q2 23
$140M
$3M
$143M
Q3 23
$133M
$3M
$136M
Q4 23
$281M
$50M
$331M
Q1 24
$271M
$28M
$299M
Q2 24
$91M
$189M
$280M
Q3 24
$80M
$174M
$254M
Q4 24
$100M
$271M
$371M
Q1 25
$85M
$233M
$318M
Q2 25
$71M
$185M
$256M
Q3 25
$75M
$129M
$204M
Q4 25
$102M
$204M
$306M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
37M
+0.4%
Q2 23
38M
+0.2%
Q3 23
38M
+2.0%
Q4 23
42M
+10.0%
Q1 24
53M
+25.5%
Q2 24
53M
+0.6%
Q3 24
54M
+2.3%
Q4 24
65M
+18.6%
Q1 25
70M
+8.1%
Q2 25
70M
+0.2%
Q3 25
70M
+0.3%
Q4 25
83M
+18.3%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 14
$145K
24
FY 15
$1M
26
FY 16
$81K
20
FY 17
$343K
22
FY 18
$67K
44
FY 19
$242K
84
FY 20
$341K
101
FY 21
$300K
123
FY 22
$288K
144
FY 23
$380K
121
FY 24
$262K
165
FY 25
$157
200K
marketcaparena.com